The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Highlights from a CLL session: BTKis, personalizing care, novel regimens, & more
Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center, New York, NY, discusses highlights from a session focused on the treatment of chronic lymphocytic leukemia (CLL). She speaks about transitioning from front-line to relapsed/refractory (R/R) care, usage of BTK inhibitors, time-limited treatments, personalizing care, and novel treatment regimens that are currently in development. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
SAB/Consultant/Honoraria: AbbVie, Adaptive Biosciences, Astra-Zeneca, Bei-Gene, Genentech,Genmab, Janssen, LOXO/Eli Lilly, Pharmacyclics
Institutional Research funding: AbbVie, Astra-Zeneca, BeiGene, Genentech, Genmab, LOXO/Eli Lilly, MingSight, Octapharma, Oncternal
